News Releases

  • Webcast Image Webcast
    Q2 2018 Clovis Oncology, Inc. Earnings Conference Call
    08/01/18 at 04:30 PM EDT
Date Title
08/08/18
Summary ToggleClovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

Trial to Evaluate the Combination of Rubraca ® (rucaparib) and OPDIVO ® (nivolumab) in Patients with Advanced Ovarian Cancer BOULDER, Colo. --(BUSINESS WIRE)--Aug. 8, 2018-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the randomization of the first patient in the Phase 3 ATHENA trial

08/01/18
Summary ToggleClovis Oncology Announces Second Quarter 2018 Operating Results

$23.8M in Rubraca ® sales for the second quarter of 2018 compared to $14.6M for Q2 2017 Rubraca approved in U.S. on April 6, 2018 for expanded ovarian cancer maintenance treatment indication Rubraca granted Marketing Authorization by European Commission on May 29 for treatment of recurrent ovarian

07/18/18
Summary ToggleClovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1

BOULDER, Colo. --(BUSINESS WIRE)--Jul. 18, 2018-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2018 financial results on Wednesday, August 1, 2018 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast

07/05/18
Summary ToggleClovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca®▼ (rucaparib) as Maintenance Treatment for Women with Recurrent Ovarian Cancer

The filing is based on positive phase 3 ARIEL3 clinical trial data in which rucaparib significantly improved progression free survival (PFS) compared to placebo in all primary efficacy ovarian cancer patient populations Timing of validation by EMA may allow for a CHMP opinion on maintenance

06/11/18
Summary ToggleClovis Oncology to Present at the Goldman Sachs 39th Annual Global Healthcare Conference 2018

BOULDER, Colo. --(BUSINESS WIRE)--Jun. 11, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 4:00 PM Pacific Time .

06/04/18
Summary ToggleClovis Oncology Submits Application to EMA to Expand Use of Rubraca®▼ (rucaparib) to Include Maintenance Treatment for Women with Recurrent Ovarian Cancer Untitled Document   Submission based on positive phase 3 ARIEL3 clinical trial in which rucaparib significantly improved PFS in all primary efficacy ovarian cancer patient populations studied Timing of maintenance treatment application submission to EMA may allow for a CHMP opinion by year-end 2018
06/03/18
Summary ToggleClovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers Companies to Start Phase 1/2 Study to Evaluate the Combination of Rubraca® (Rucaparib) and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial Cancer BOULDER, Colo. and MORRIS PLAINS, N.J. , June 03, 2018 (GLOBE NEWSWIRE) -- Clovis Oncology,
05/29/18
Summary ToggleClovis Oncology Announces European Commission Authorization of Rubraca® (rucaparib) for Women with Recurrent Ovarian Cancer First PARP inhibitor licensed for ovarian treatment indication in the EU New option for women with recurrent BRCA mutant ovarian cancer with platinum-sensitive, relapsed or progressive disease, who are unable to tolerate further platinum-based chemotherapy BOULDER, Colo.
05/16/18
Summary ToggleClovis Oncology Announces Presentations at 2018 ASCO Annual Meeting

Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, as well as trials in progress presentations of Rubraca ® (rucaparib) in multiple solid tumor settings at ASCO BOULDER, Colo. --(BUSINESS WIRE)--May 16, 2018-- Clovis Oncology, Inc.

05/09/18
Summary ToggleClovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018

BOULDER, Colo. --(BUSINESS WIRE)--May 9, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2018 on Thursday, May 17, 2018 at 10:00 AM Pacific Time .

05/09/18
Summary ToggleCORRECTING and REPLACING Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018

BOULDER, Colo. --(BUSINESS WIRE)--May 9, 2018-- Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time (instead of Thursday, May 17, 2018 at 10:00 AM Pacific Time). The corrected release reads: CLOVIS ONCOLOGY TO PRESENT AT THE

05/08/18
Summary ToggleClovis Oncology Announces First Quarter 2018 Operating Results

$18.5M in Rubraca ® sales for the first quarter of 2018, based on limited third-line BRCA-mutant ovarian cancer treatment label in U.S. All-comers and earlier-line ovarian cancer maintenance treatment indication approved in U.S. on April 6, 2018 CHMP adopted positive opinion for limited treatment

04/24/18
Summary ToggleClovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8

BOULDER, Colo. --(BUSINESS WIRE)--Apr. 24, 2018-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2018 financial results on Tuesday, May 8, 2018 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30

04/16/18
Summary ToggleClovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock

BOULDER, Colo. --(BUSINESS WIRE)--Apr. 16, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public of 100% of the

04/16/18
Summary ToggleClovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock

BOULDER, Colo. --(BUSINESS WIRE)--Apr. 16, 2018-- Clovis Oncology , Inc. (NASDAQ:CLVS) announced today that it has commenced two separate underwritten public offerings of convertible senior notes and common stock. Clovis intends to offer, subject to market and other conditions, $200 million

04/06/18
Summary ToggleRubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer

Rubraca is now indicated as maintenance treatment for women with recurrent ovarian cancer who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA mutation status – no biomarker testing required Rubraca received regular approval in this broader and earlier-line

03/23/18
Summary ToggleClovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe BOULDER, Colo. --(BUSINESS WIRE)--Mar. 23, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor
03/23/18
Summary ToggleCHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets Rubraca offers a new option for women with advanced BRCA mutant ovarian cancer with platinum-sensitive, relapsed or progressive disease, who are unable to tolerate further platinum based chemotherapy First PARP inhibitor recommended for treatment indication in the EU European Commission (EC) formal
03/08/18
Summary ToggleClovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035 • Claims to be issued cover all commercial dosage strengths of Rubraca ® • This will be the 10 th Orange Book-listed patent for Rubraca BOULDER, Colo. --(BUSINESS WIRE)--Mar. 8, 2018-- Clovis Oncology , Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the
03/07/18
Summary ToggleClovis Oncology to Present at the Barclays Global Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Mar. 7, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 8:00 AM Eastern Time .
02/26/18
Summary ToggleClovis Oncology Announces 2017 Operating Results First full year of Rubraca ® (rucaparib) U.S. sales totaled $55.5M , including $17.0M for the fourth quarter of 2017, with limited third-line BRCA-mutant ovarian cancer treatment label U.S. maintenance treatment indication under review, with April 6, 2018 PDUFA date CHMP positive trend vote
02/21/18
Summary ToggleClovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication The CHMP has communicated a positive trend vote for the rucaparib MAA under review for the treatment of women with advanced BRCA-mutant ovarian cancer and expects to vote on the treatment indication at their scheduled meeting in March 2018 Pending a positive recommendation by CHMP, final approval
02/12/18
Summary ToggleClovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 12, 2018-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live
01/04/18
Summary ToggleClovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Jan. 4, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy , will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 PM Pacific Time .
12/19/17
Summary ToggleRucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018 Treatment indication remains under active review The Scientific Advisory Group advice will assist CHMP to reach a positive or negative opinion In January 2018 , the Company plans to notify the EMA of its intent to submit a new MAA in Q2 2018 for the maintenance treatment indication in women with
12/05/17
Summary ToggleClovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application Clovis seeks U.S. approval for rucaparib as maintenance therapy for women with recurrent ovarian cancer who are platinum sensitive, and in complete or partial response to platinum chemotherapy, with no requirement for diagnostic testing Priority review granted based on positive data from phase 3
11/08/17
Summary ToggleClovis Oncology to Present at the Stifel 2017 Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Nov. 8, 2017-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy , will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 9:30 AM Eastern Time .
11/01/17
Summary ToggleClovis Oncology Announces Third Quarter 2017 Operating Results Strong third quarter of launch for Rubraca ® (rucaparib) in U.S. with $16.8M reported in net sales An additional $4.4M in commercial value was provided as free drug through our patient assistance program Submission of a supplemental New Drug Application (sNDA) for rucaparib as maintenance treatment
10/23/17
Summary ToggleClovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1 BOULDER, Colo. --(BUSINESS WIRE)--Oct. 23, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2017 financial results on Wednesday, November 1, 2017 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast
10/09/17
Summary ToggleClovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer Filing based on positive phase 3 ARIEL3 clinical trial in which rucaparib significantly improved PFS in all ovarian cancer patient populations studied Company plans to file Marketing Authorization Application in Europe in early 2018 for maintenance treatment indication BOULDER, Colo.
09/13/17
Summary ToggleClovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet ARIEL3 evaluated rucaparib as maintenance treatment among women with advanced ovarian cancer Study successfully achieved primary, key secondary and exploratory endpoints Company plans to submit a supplemental New Drug Application (sNDA) in the U.S. for maintenance treatment indication in ovarian
09/07/17
Summary ToggleClovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 ARIEL3 study successfully achieved its primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied (tumor BRCA-mutant, HRD and overall intent-to-treat) ARIEL3 study also successfully achieved the key secondary endpoint of improved PFS
08/30/17
Summary ToggleClovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress Comprehensive results from Phase 3 ARIEL3 maintenance treatment trial of rucaparib in advanced ovarian cancer patients accepted as late-breaker presentation, will be highlighted in ESMO press program Posters outlining the designs of the ARIEL4 and TRITON clinical trial programs will also be
08/02/17
Summary ToggleClovis Oncology Announces Second Quarter 2017 Operating Results Strong second quarter of launch for Rubraca ® (rucaparib) in U.S. with $14.6M reported in net sales Positive topline data from the ARIEL3 study reported on June 19, 2017 ; presentation of full dataset confirmed at European Society for Medical Oncology 2017 Congress in Madrid Clovis plans to submit
07/31/17
Summary ToggleBristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo® (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types Pivotal Phase 3 Trials Planned for 2017 will Evaluate Rubraca in Combination with Opdivo, Rubraca as Monotherapy, and Opdivo as Monotherapy in First Line Maintenance Treatment for Advanced Ovarian and Advanced Triple-Negative Breast Cancers Phase 2 Trial will Evaluate Opdivo in Combination with
07/19/17
Summary ToggleClovis Oncology to Announce Second Quarter 2017 Financial Results and Host Webcast Conference Call on August 2 BOULDER, Colo. --(BUSINESS WIRE)--Jul. 19, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2017 financial results on Wednesday, August 2, 2017 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast
06/21/17
Summary ToggleClovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jun. 21, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares.
06/20/17
Summary ToggleClovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jun. 20, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share, before underwriting discounts and commissions.
06/19/17
Summary ToggleClovis Oncology Announces Proposed Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jun. 19, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million . All shares of the common stock to be sold in the
06/19/17
Summary ToggleClovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial The ARIEL3 study successfully achieved its primary endpoint of improved PFS by investigator review in all three primary efficacy analyses: tumor BRCA-mutant, HRD-positive and overall intent-to-treat populations The ARIEL3 study successfully achieved the key secondary endpoint of improved PFS by
05/23/17
Summary ToggleClovis Oncology Announces Presentations at 2017 ASCO Annual Meeting Updates on rucaparib clinical trials in multiple solid tumors and therapy settings at ASCO Annual Meeting; top-line data from ARIEL3 pivotal study anticipated by end of June BOULDER, Colo. --(BUSINESS WIRE)--May 23, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts
05/03/17
Summary ToggleClovis Oncology Announces First Quarter 2017 Operating Results Strong Q1 launch quarter for Rubraca ® (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3 target progression events achieved in mid-April Top-line ARIEL3 data anticipated by end of June Multiple clinical trials initiated in early 2017, including TRITON2 and TRITON3 in
04/27/17
Summary ToggleMyriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment SALT LAKE CITY, Utah & BOULDER, Colo., April 27, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca.
04/20/17
Summary ToggleClovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3 BOULDER, Colo. --(BUSINESS WIRE)--Apr. 20, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at
03/28/17
Summary ToggleClovis Oncology Announces Data Presentations at AACR Annual Meeting 2017 Abstracts provide new insights into rucaparib’s mechanism of action and function in multiple disease and therapy settings FDA approved Rubraca ® (rucaparib) tablets in late 2016 as monotherapy treatment for women with BRCA-mutated advanced ovarian cancer BOULDER, Colo. --(BUSINESS WIRE)--Mar.
03/12/17
Summary ToggleClovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer New rucaparib data presented today in two oral plenary sessions Data provide additional insights from ARIEL2 Phase 2 study of rucaparib in advanced ovarian cancer FDA approved Rubraca ® (rucaparib) tablets in December 2016 as monotherapy treatment for women with BRCA-mutated advanced ovarian cancer
02/22/17
Summary ToggleClovis Oncology Announces 2016 Operating Results Rubraca™ (rucaparib) approved and launched in the U.S. on December 19, 2016 for the treatment of advanced BRCA-mutant ovarian cancer $266.2M in cash, cash equivalents and available for sale securities at December 31, 2016 $487.4M in adjusted cash, cash equivalents and available for sale securities
02/09/17
Summary ToggleClovis Oncology to Announce Fourth Quarter/Year-End 2016 Financial Results and Host Webcast Conference Call on February 22 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 9, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2016 financial results on Wednesday, February 22, 2017 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live
02/01/17
Summary ToggleClovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program Strata Trial to Identify Genetically Selected Patients Eligible for Enrollment in Clovis’ TRITON Studies in Advanced Prostate Cancer BOULDER, Colo. & ANN ARBOR, Mich. --(BUSINESS WIRE)--Feb. 1, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc.
01/09/17
Summary ToggleClovis Oncology to Present at the 35th Annual J.P. Morgan Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Jan. 9, 2017-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy , will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 2:30 PM Pacific Time .
01/04/17
Summary ToggleClovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jan. 4, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares.
01/03/17
Summary ToggleClovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jan. 3, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.00 per share, before underwriting discounts and commissions.
01/03/17
Summary ToggleClovis Oncology Announces Proposed Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jan. 3, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million . All shares of the common stock to be sold in the
12/19/16
Summary ToggleADDING MULTIMEDIA and CONFERENCE CALL DETAILS Clovis Oncology Announces FDA Accelerated Approval of RUBRACA™ (rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germline or Somatic BRCA Mutations... First and only PARP inhibitor in the U.S. indicated to treat advanced ovarian cancer patients who have been treated with two or more chemotherapies and who have deleterious germline or somatic BRCA mutations Rubraca received approval under the FDA’s accelerated approval program based on objective
12/19/16
Summary ToggleClovis Oncology Announces FDA Accelerated Approval of RUBRACA™ (rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germline or Somatic BRCA Mutations Treated with Two or More Chemotherapies First and only PARP inhibitor in the U.S. indicated to treat advanced ovarian cancer patients who have been treated with two or more chemotherapies and who have deleterious germline or somatic BRCA mutations Rubraca received approval under the FDA’s accelerated approval program based on objective
11/03/16
Summary ToggleClovis Oncology Announces Q3 2016 Operating Results and Corporate Update Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant ovarian cancer; PDUFA date February 23, 2017 Rucaparib MAA submission submitted this week Clovis commercial and medical affairs organizations preparing for potential U.S.
10/31/16
Summary ToggleClovis Oncology to Present at the 2016 Credit Suisse Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Oct. 31, 2016-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick Mahaffy , the Company’s President and CEO, will present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8 , at 1:00pm MST .
10/27/16
Summary ToggleClovis Oncology to Announce Third Quarter 2016 Financial Results and Host Webcast Conference Call on November 3 BOULDER, Colo. --(BUSINESS WIRE)--Oct. 27, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2016 financial results on Thursday, November 3, 2016 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast
10/07/16
Summary ToggleClovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress Rucaparib NDA Dataset to be presented in oral presentation today at ESMO Rucaparib NDA currently under priority review with FDA Prescription Drug User Fee Act (PDUFA) date is February 23, 2017 European Marketing Authorization Application (MAA) submission planned for Q4 2016 BOULDER, Colo.
09/28/16
Summary ToggleClovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress Data for rucaparib in the treatment of advanced ovarian cancer to be highlighted in oral presentation U.S. Food and Drug Administration ( FDA ) accepted accelerated approval application for review and granted priority review status Prescription Drug User Fee Act (PDUFA) date is February 23, 2017
08/23/16
Summary ToggleFDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer Seeking approval for mutant BRCA patients treated with two or more prior therapies FDA Grants Priority Review Status Assigns PDUFA Date of February 23, 2017 BOULDER, Colo. --(BUSINESS WIRE)--Aug. 23, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S.
08/08/16
Summary ToggleClovis Oncology Announces Q2 2016 Operating Results and Corporate Update Rucaparib NDA submission completed in late June for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors FDA decision on filing and determination of PDUFA date is anticipated in late August Rucaparib MAA submission on track for Q4 2016 Rucaparib NDA dataset
07/26/16
Summary ToggleClovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8 BOULDER, Colo. --(BUSINESS WIRE)--Jul. 26, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2016 financial results on Monday, August 8, 2016 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at
06/06/16
Summary ToggleClovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting BOULDER, Colo. --(BUSINESS WIRE)--Jun. 6, 2016-- Clovis Oncology  (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in pancreatic cancer at the
05/19/16
Summary ToggleClovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting New rucaparib data to be highlighted in poster presentations Rolling New Drug Application (NDA) submission for rucaparib for the treatment of patients with advanced ovarian cancer expected to complete during Q2 2016 European Marketing Authorization Application (MAA) planned in Q4 2016 BOULDER,
05/05/16
Summary ToggleClovis Oncology Announces Q1 2016 Operating Results and Corporate Update Rucaparib rolling NDA submission initiated for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors and expected to complete Q2 2016 Rucaparib MAA submission planned Q4 2016 Clovis preparing for potential U.S. commercial launch of rucaparib with existing
04/26/16
Summary ToggleClovis Oncology to Announce First Quarter 2016 Financial Results and Host Webcast Conference Call on May 5 BOULDER, Colo. --(BUSINESS WIRE)--Apr. 26, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at
04/12/16
Summary ToggleClovis Oncology Provides Update on FDA Oncologic Drugs Advisory Committee Meeting to Review Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer BOULDER, Colo. --(BUSINESS WIRE)--Apr. 12, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss approval of the New Drug Application (NDA) for rociletinib, an investigational therapy for
04/12/16
Summary ToggleTrading of Clovis Oncology, Inc. Common Stock Halted FDA’s Oncologic Drugs Advisory Committee to Review Rociletinib New Drug Application for the Treatment of Non-Small Cell Lung Cancer BOULDER, Colo. --(BUSINESS WIRE)--Apr. 12, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company’s common stock.
04/08/16
Summary ToggleFDA Posts Briefing Documents for Advisory Committee Meeting to Review Clovis Oncology’s Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer BOULDER, Colo. --(BUSINESS WIRE)--Apr. 8, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration ( FDA ) posted briefing materials in advance of the Oncologic Drugs Advisory Committee (ODAC) meeting to discuss accelerated approval of the New Drug
02/25/16
Summary ToggleClovis Oncology Announces 2015 Operating Results Rociletinib NDA scheduled for discussion at ODAC panel on April 12 with a June 28 PDUFA date Rucaparib NDA submission for treatment of advanced ovarian cancer expected to complete Q2 2016 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 25, 2016-- Clovis Oncology , Inc.
02/16/16
Summary ToggleClovis Oncology to Announce Fourth Quarter/Year-End 2015 Financial Results and Host Webcast Conference Call on February 25 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 16, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2015 financial results on Thursday, February 25, 2016 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live
02/12/16
Summary ToggleClovis Oncology Announces Rociletinib New Drug Application Scheduled for Presentation at Upcoming FDA Oncologic Drugs Advisory Committee Meeting BOULDER, Colo. --(BUSINESS WIRE)--Feb. 12, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration ( FDA ) has scheduled the New Drug Application (NDA) for rociletinib for discussion by the Oncologic Drugs Advisory Committee (ODAC) on April 12, 2016 .
01/27/16
Summary ToggleClovis Oncology Initiates Immunotherapy Combination Trial Study to evaluate the combination of rociletinib (CO-1686) with Genentech’s atezolizumab (MPDL3280A) for patients with advanced EGFR-mutant non-small cell lung cancer BOULDER, Colo. --(BUSINESS WIRE)--Jan. 27, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it initiated a clinical
01/25/16
Summary ToggleClovis Oncology Appoints Dale Hooks as Chief Commercial Officer Hooks, Clovis’ Vice President of Sales since 2014, has been instrumental in building out the Company’s commercial organization BOULDER, Colo. --(BUSINESS WIRE)--Jan. 25, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Dale Hooks has been named Senior Vice President and Chief
01/06/16
Summary ToggleClovis Oncology to Present at the 34th Annual J.P. Morgan Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Jan. 6, 2016-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy , will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016 at 11:00 AM Pacific Time .
12/15/15
Summary ToggleClovis Oncology Receives Notification of PDUFA Extension for Rociletinib PDUFA goal date extended by three months to June 28, 2016 BOULDER, Colo. --(BUSINESS WIRE)--Dec. 15, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration ( FDA ) has extended the Prescription Drug User Fee Act (PDUFA) date for Clovis’ New Drug
11/16/15
Summary ToggleClovis Oncology Announces Regulatory Update for Rociletinib NDA Filing Mid-Cycle Communication Meeting with FDA completed Additional clinical information for 500mg and 625mg BID dose groups to be provided by the Company today BOULDER, Colo. --(BUSINESS WIRE)--Nov. 16, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that during its regularly scheduled
11/05/15
Summary ToggleClovis Oncology Announces Third Quarter 2015 Operating Results New Drug Application (NDA) for rociletinib for the treatment of advanced EGFR-mutant T790M+ non-small cell lung cancer (NSCLC) on file with U.S. FDA Marketing Authorization Application (MAA) for rociletinib on file in E.U.; action expected mid-2016 Raised $298 million in July equity offering
11/03/15
Summary ToggleClovis Oncology to Present at the 2015 Credit Suisse Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Nov. 3, 2015-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast , the Company’s Executive Vice President and CFO, will present at the 2015 Credit Suisse Healthcare Conference on Tuesday, November 10 , at 1:30pm MST .
10/22/15
Summary ToggleClovis Oncology to Announce Third Quarter 2015 Financial Results and Host Webcast Conference Call on November 5 BOULDER, Colo. --(BUSINESS WIRE)--Oct. 22, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2015 financial results on Thursday, November 5, 2015 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast
09/29/15
Summary ToggleClovis Oncology Announces U.S. and E.U. Regulatory Milestones for Rociletinib in the Treatment of Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer FDA Grants Priority Review Status to Rociletinib New Drug Application; Assigns Action Date of March 30, 2016 EMA Accepts Marketing Authorization Application for Rociletinib; Awards Accelerated Assessment BOULDER, Colo. --(BUSINESS WIRE)--Sep. 29, 2015-- Clovis Oncology, Inc.
09/23/15
Summary ToggleClovis Oncology Announces Data Presentations at 2015 European Cancer Congress Three oral presentations and four scientific posters selected for presentation at the European Cancer Congress in Vienna, Austria Rucaparib oral presentation on Tuesday, September 29 to include final outcomes data from full ARIEL2 part 1 population of 206 women with advanced ovarian cancer Clinical
09/10/15
Summary ToggleClovis Oncology to Present at the Morgan Stanley Global Healthcare Conference 2015 BOULDER, Colo. --(BUSINESS WIRE)--Sep. 10, 2015-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy , will present at the Morgan Stanley Global Healthcare Conference 2015 on Thursday, September 17, 2015 at 12:20 PM Eastern Time .
09/04/15
Summary ToggleClovis Oncology Announces Data Presentations at 16th World Conference on Lung Cancer Four rociletinib mini-oral presentations and two scientific posters debuting at World Conference on Lung Cancer in Denver BOULDER, Colo. --(BUSINESS WIRE)--Sep. 4, 2015-- Clovis Oncology (NASDAQ:CLVS) today announced that rociletinib, the company’s oral targeted covalent (irreversible)
08/11/15
Summary ToggleClovis Oncology Enters into Clinical Trial Collaboration Study to evaluate the combination of rociletinib (CO-1686) with Genentech’s atezolizumab (MPDL3280A) for patients with advanced EGFR-mutant non-small cell lung cancer BOULDER, Colo. --(BUSINESS WIRE)--Aug. 11, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a
08/06/15
Summary ToggleClovis Oncology Announces Second Quarter 2015 Operating Results Completed rociletinib (CO-1686) U.S. NDA and E.U. MAA regulatory submissions in July for patients with EGFR-mutant non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the T790M mutation Preparing for potential Q4 2015 U.S.
08/03/15
Summary ToggleClovis Oncology Completes U.S. and E.U. Regulatory Submissions for Rociletinib for the Treatment of Advanced EGFR-Mutant T790M+ Non-small Cell Lung Cancer New Drug Application submitted to U.S. Food and Drug Administration and Marketing Authorization Application submitted to European Medicines Agency BOULDER, Colo. --(BUSINESS WIRE)--Aug. 3, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it has submitted its New Drug Application
07/23/15
Summary ToggleClovis Oncology to Announce Second Quarter 2015 Financial Results and Host Webcast Conference Call on August 6 BOULDER, Colo. --(BUSINESS WIRE)--Jul. 23, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2015 financial results on Thursday, August 6, 2015 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at
07/10/15
Summary ToggleClovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jul. 10, 2015-- Clovis Oncology (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 528,846 shares.
07/08/15
Summary ToggleClovis Oncology Announces Pricing of Public Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jul. 8, 2015-- Clovis Oncology (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,525,641 shares of its common stock at $78.00 per share, before underwriting discounts and commissions. In addition, the underwriters have a 30-day
07/07/15
Summary ToggleClovis Oncology Announces Proposed Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jul. 7, 2015-- Clovis Oncology (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $275 million . All shares of the common stock to be sold in the offering
07/01/15
Summary ToggleClovis Oncology Initiates Rolling NDA Submission to the FDA for Rociletinib in the Treatment of Advanced EGFR-Mutant Non-small Cell Lung Cancer NDA submission is expected to complete by late July BOULDER, Colo. --(BUSINESS WIRE)--Jul. 1, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it has commenced the submission of a New Drug Application (NDA) regulatory filing to the U.S.
06/22/15
Summary ToggleClovis Oncology Appoints Dr. Lindsey Rolfe as Chief Medical Officer Dr. Rolfe, currently Clovis’ Senior Vice President of Clinical Development, oversees the rociletinib and rucaparib development programs Dr. Andrew Allen stepping down after rociletinib NDA/MAA submissions to create a new biotech company and serve as its CEO BOULDER, Colo. --(BUSINESS WIRE)--Jun.
05/31/15
Summary ToggleClovis Oncology’s Rociletinib (CO-1686) Phase 2 Study Results Demonstrate Consistent and Promising Clinical Activity and Disease Control in Very Advanced Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 60% overall response rate (ORR) and 90% disease control rate (DCR) in heavily pretreated centrally confirmed tissue T790M-positive patients Median progression free survival (PFS) of 10.3 months observed in patients without a history of CNS metastases; median PFS of 8 months observed in overall
05/30/15
Summary ToggleClovis Oncology’s Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Highly Compelling Clinical Activity, in Both BRCA-mutant and BRCA-like Patients, Together Comprising Approximately 60 Percent of Patients Data from ARIEL2 in platinum-sensitive BRCA-mutant patients demonstrated an overall response rate (ORR) of 82%, a disease control rate (DCR) of 94% and a median progression-free survival (PFS) of 9.4 months Complete responses (CRs) observed in 10% of patients Data from ARIEL2 in patients with
05/13/15
Summary ToggleClovis Oncology Announces Data Presentations at 2015 ASCO Annual Meeting Rociletinib oral presentation on Sunday, May 31 to update TIGER-X clinical data in heavily pretreated, advanced EGFR-mutant lung cancer patients, including in plasma-genotyped T790M-positive patients Rucaparib oral presentation on Monday, June 1 to include outcomes data from full ARIEL2 part one
05/06/15
Summary ToggleClovis Oncology Announces First Quarter 2015 Operating Results Rociletinib (CO-1686) rolling NDA submission for EGFR-mutant lung cancer expected to commence in June, and complete by July/August Launch planning underway for potential late 2015 U.S. launch of rociletinib Phase 1/2 rociletinib data published in April 30 issue of the New England Journal of
04/23/15
Summary ToggleClovis Oncology to Announce First Quarter 2015 Financial Results and Host Webcast Conference Call on May 6 BOULDER, Colo. --(BUSINESS WIRE)--Apr. 23, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2015 financial results on Wednesday, May 6, 2015 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at
04/06/15
Summary ToggleClovis Oncology Receives Breakthrough Therapy Designation for Rucaparib for Monotherapy Treatment of Advanced Ovarian Cancer in Patients with BRCA-mutated Tumors (Inclusive of both Germline and Somatic BRCA Mutations) Only PARP inhibitor to receive Breakthrough Therapy designation Rucaparib NDA filing for treatment of advanced platinum-sensitive ovarian cancer planned for 2016 Second Breakthrough Designation granted to a Clovis Oncology drug candidate BOULDER, Colo. --(BUSINESS WIRE)--Apr.
02/25/15
Summary ToggleClovis Oncology Announces 2014 Operating Results Rociletinib (CO-1686) NDA and MAA submissions for EGFR-mutant lung cancer planned mid-2015 Rucaparib development program accelerated; filing now planned for treatment of platinum-sensitive ovarian cancer in 2016 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 25, 2015-- Clovis Oncology , Inc.
02/17/15
Summary ToggleClovis Oncology to Announce Fourth Quarter/Year-End 2014 Financial Results and Host Webcast Conference Call on February 25 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 17, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2014 financial results on Wednesday, February 25, 2015 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live
02/04/15
Summary ToggleClovis Oncology to Present at the 2015 Leerink Global Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Feb. 4, 2015-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast , the Company’s executive vice president and CFO, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12 , at 1:25 p.m. EST .
01/05/15
Summary ToggleClovis Oncology to Present at the 33rd Annual J.P. Morgan Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Jan. 5, 2015-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy , will present at the 33 rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 1:30 PM Pacific Time .
11/19/14
Summary ToggleInitial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients Clovis’ “BRCAness” DNA signature predicts which patients respond to rucaparib therapy Overall response rate (ORR) of 70% in BRCA-mutant patients; responses observed in patients with both germline and somatic mutations ORR of 40% in patients with BRCAness signature (all BRCA wild-type) ORR of only
11/18/14
Summary ToggleInterim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) 67% objective response rate (ORR) observed in evaluable heavily-pretreated T790M+ patients treated with 625mg or 500mg BID (clinical dose group) Median PFS of 10.4 months in clinical dose group; data continue to mature Well-tolerated – majority of treatment-related adverse events are grade 1-2 In
11/17/14
Summary ToggleClovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline Study to evaluate the combination of rociletinib (CO-1686) with trametinib for patients with advanced or metastatic mutant EGFR NSCLC BOULDER, Colo. --(BUSINESS WIRE)--Nov. 17, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration
11/12/14
Summary ToggleClovis Oncology Announces First Patient Enrolled in TIGER-1 Study Study to compare rociletinib (CO-1686) to standard-of-care erlotinib as treatment for patients with newly-diagnosed EGFR-mutant advanced non-small cell lung cancer (NSCLC) BOULDER, Colo. --(BUSINESS WIRE)--Nov. 12, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion
11/06/14
Summary ToggleClovis Oncology Announces Third Quarter 2014 Operating Results Data updates for rucaparib and rociletinib to be presented in oral presentations at the ENA Symposium November 20 and 21 $278.3 million raised in September sale of senior convertible notes Encouraging rucaparib data in ovarian cancer presented at ESMO First patients enrolled in lucitanib Phase 2
11/04/14
Summary ToggleClovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Nov. 4, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s President and CEO, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, November 11 , at 2:00pm MST .
10/23/14
Summary ToggleClovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer BOULDER, Colo. --(BUSINESS WIRE)--Oct. 23, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site.
10/22/14
Summary ToggleClovis Oncology to Announce Third Quarter 2014 Financial Results and Host Webcast Conference Call on November 6 BOULDER, Colo. --(BUSINESS WIRE)--Oct. 22, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2014 financial results on Thursday, November 6, 2014 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast
09/28/14
Summary ToggleData from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy Encouraging disease control rate of 93 percent, RECIST response rate of 71 percent observed in Phase 2 study of ovarian cancer patients with BRCA mutations; no drug discontinuations due to treatment-related adverse events 56 percent of non-mutant BRCA patients in the ARIEL2 study to date exhibit
09/10/14
Summary ToggleClovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in FGF-aberrant Advanced Breast Cancer BOULDER, Colo. --(BUSINESS WIRE)--Sep. 10, 2014-- Clovis Oncology (NASDAQ:CLVS) today announced that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site. Lucitanib is the Company’s oral, potent inhibitor
09/09/14
Summary ToggleClovis Oncology Announces Exercise in Full by Initial Purchasers of Their Option to Purchase an Additional $37.5 Million Aggregate Principal Amount of the Company’s 2.50% Convertible Senior Notes Due 2021 BOULDER, Colo. --(BUSINESS WIRE)--Sep. 9, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the initial purchasers of the previously announced offering of the Company’s 2.50% Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers
09/08/14
Summary ToggleClovis Oncology to Present at the 2014 Morgan Stanley Global Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Sep. 8, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s president and CEO, will present at the 2014 Morgan Stanley Global Healthcare Conference on Tuesday, September 9 , at 4:05pm EST .
09/03/14
Summary ToggleClovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes BOULDER, Colo. --(BUSINESS WIRE)--Sep. 3, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of $250 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the
09/02/14
Summary ToggleClovis Oncology to Offer $200 Million of Convertible Senior Notes BOULDER, Colo. --(BUSINESS WIRE)--Sep. 2, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of its convertible senior notes due 2021 (the “notes”) in a private placement to qualified
08/07/14
Summary ToggleClovis Oncology Announces Second Quarter 2014 Operating Results CO-1686 NDA submission expected by mid-2015 CO-1686 Breakthrough Therapy designation granted during Q2 Proposed INN rociletinib assigned to CO-1686 Rociletinib and rucaparib data updates to be presented at medical conferences in Fall 2014 BOULDER, Colo. --(BUSINESS WIRE)--Aug.
07/21/14
Summary ToggleClovis Oncology to Announce Second Quarter 2014 Financial Results and Host Webcast Conference Call on August 7 BOULDER, Colo. --(BUSINESS WIRE)--Jul. 21, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its second quarter 2014 financial results on Thursday, August 7, 2014 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at
06/23/14
Summary ToggleClovis Oncology Announces First Patient Enrolled in TIGER2 Study Study to evaluate CO-1686 as treatment for second-line mutant EGFR NSCLC patients with confirmed T790M resistance mutation BOULDER, Colo. --(BUSINESS WIRE)--Jun. 23, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the TIGER2 study has commenced with the dosing of the first patient
06/16/14
Summary ToggleClovis Oncology Announces First Patient Enrolled in RUCAPANC Study Study to evaluate PARP inhibitor rucaparib as treatment for locally advanced or metastatic pancreatic cancer with a deleterious BRCA mutation BOULDER, Colo. --(BUSINESS WIRE)--Jun. 16, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the RUCAPANC (Rucaparib Assessment in
05/31/14
Summary ToggleClovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1/2 Study Results in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) 58% objective response rate observed to date in 40 evaluable heavily-pretreated T790M+ patients in Phase 1 and early Phase 2 expansion cohorts Current estimate of median PFS greater than 12 months in T790M+ patient population; observed median not yet reached Well-tolerated – majority of
05/31/14
Summary ToggleClovis Oncology’s Phase 1 Study of Rucaparib Demonstrates Compelling Clinical Activity and Safety in Patients with Solid Tumors After 24 weeks of rucaparib monotherapy, 82 percent disease control rate observed in ovarian cancer patients with BRCA mutations No drug discontinuations because of treatment-related adverse events in Phase 1 study Rucaparib at recommended Phase 2 dose of 600 mg BID showed strong activity with good
05/31/14
Summary ToggleClovis Oncology Announces Encouraging Data from Phase 1/2a Study Evaluating Lucitanib in Advanced Solid Tumors Durable clinical responses observed in patients with both FGF-aberrant and angiogenic-sensitive tumor types In heavily-pretreated FGF-aberrant breast cancer patients, a 50 percent objective response rate and 9.6 months progression-free survival were observed Most drug-related adverse events were
05/19/14
Summary ToggleClovis Oncology Receives Breakthrough Therapy Designation for CO-1686 for the Treatment of Second-line EGFR Mutant Non-small Cell Lung Cancer (NSCLC) in Patients with the T790M Mutation BOULDER, Colo. --(BUSINESS WIRE)--May 19, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy designation for the Company’s investigational agent CO-1686 as monotherapy for the treatment of second-line EGFR
05/14/14
Summary ToggleClovis Oncology Announces Clinical Data to Be Presented at 2014 ASCO Annual Meeting Abstracts provide updates on the Company’s three investigational therapies in development: - CO-1686, an oral, novel mutant EGFR inhibitor for non-small cell lung cancer (NSCLC) - Rucaparib, an oral PARP inhibitor for ovarian cancer, and - Lucitanib, an oral tyrosine-kinase inhibitor for breast
05/08/14
Summary ToggleClovis Oncology Announces First Quarter 2014 Operating Results Encouraging CO-1686 clinical activity and progression-free survival (PFS) in non-small cell lung cancer (NSCLC) reported at European Lung Cancer Conference in late March; CO-1686 Phase 2 expansion cohorts enrolling TIGER1 and TIGER2 studies to initiate shortly CO-1686 New Drug Application (NDA)
04/28/14
Summary ToggleClovis Oncology to Announce First Quarter 2014 Financial Results and Host Webcast Conference Call on May 8 BOULDER, Colo. --(BUSINESS WIRE)--Apr. 28, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its first quarter 2014 financial results on Thursday, May 8, 2014 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on
04/03/14
Summary ToggleFoundation Medicine and Clovis Oncology Expand Collaboration to Develop Novel Companion Diagnostic for Rucaparib in Ovarian Cancer Companion diagnostic development builds upon regulatory strategy for Foundation Medicine’s comprehensive genomic profiling platform and differentiated clinical development strategy for Clovis Oncology CAMBRIDGE, Mass. & BOULDER, Colo.--( BUSINESS WIRE )-- Foundation Medicine, Inc.
03/27/14
Summary ToggleClovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC) 64% objective response rate observed in T790M+ patients PFS greater than six months in heavily-pretreated T790M+ patient population; median not yet reached Well-tolerated – only one of 62 patients treated at therapeutic doses of CO-1686 discontinued because of adverse events Only TKI to completely
02/27/14
Summary ToggleClovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program CO-1686 Phase 2 expansion cohorts increased in size to approximately 300 patients Potential to accelerate NDA submission timeline BOULDER, Colo. --(BUSINESS WIRE)--Feb. 27, 2014-- Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for its quarter and year ended December 31, 2013 , and
02/18/14
Summary ToggleClovis Oncology to Announce Fourth Quarter/Year End 2013 Financial Results and Host Webcast Conference Call on February 27 BOULDER, Colo. , Feb. 18, 2014 (GLOBE NEWSWIRE) -- Clovis Oncology, Inc. (Nasdaq:CLVS) will announce its fourth quarter/year end 2013 financial results on Thursday, February 27, 2014 , after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live
02/06/14
Summary ToggleClovis Oncology to Present at the 2014 Leerink Global Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Feb. 6, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s president and CEO, will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13 , at 11:25am MST .
01/13/14
Summary ToggleClovis Oncology Announces 2014 Objectives and Financial Guidance BOULDER, Colo. --(BUSINESS WIRE)--Jan. 13, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced anticipated development milestones and financial guidance for 2014. Clovis currently has three clinical development programs underway, and expects to initiate four registration studies for two of
01/06/14
Summary ToggleClovis Oncology to Present at the 32nd Annual J.P. Morgan Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Jan. 6, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy , will present at the 32 nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 3:30 PM Pacific Time .
12/23/13
Summary ToggleClovis Oncology Announces CO-1686 Clinical Data Accepted as Oral Presentation at 2014 European Lung Cancer Conference BOULDER, Colo. --(BUSINESS WIRE)--Dec. 23, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today that an abstract discussing the findings of the ongoing Phase I portion of the Phase I/II clinical study of CO-1686 has been accepted for Proffered Paper (Oral) presentation during the 4 th European Lung
12/03/13
Summary ToggleClovis Oncology Announces Sale of Shares of Common Stock by Selling Stockholders BOULDER, Colo. --(BUSINESS WIRE)--Dec. 3, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $57.50 per share. All of the shares are being sold by certain existing
12/02/13
Summary ToggleClovis Oncology Announces Proposed Secondary Offering of Shares of Common Stock by Selling Stockholders No new shares of common stock being sold by the Company BOULDER, Colo. --(BUSINESS WIRE)--Dec. 2, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that certain selling stockholders have commenced an underwritten public offering of 2,000,000 shares of the Company’s common stock which they
11/19/13
Summary ToggleClovis Oncology Acquires EOS (Ethical Oncology Science) S.p.A. to Gain Rights to Lucitanib, a Unique Dual-Selective Phase II FGFR/VEGFR Inhibitor 50 percent response rate seen in heavily-pretreated FGF-aberrant breast cancer patients Activity observed in other solid tumors with FGFR/VEGFR pathway activation Servier partnership to fund majority of lucitanib R&D expenditures over the next 2-3 years Adds third compound to portfolio with focus
11/05/13
Summary ToggleClovis Oncology to Present at the Credit Suisse Annual Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Nov. 5, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast , the Company’s executive vice president and CFO, will present at the Credit Suisse Annual Healthcare Conference on Tuesday, November 12 , at 4:00pm MST .
10/31/13
Summary ToggleClovis Oncology Announces Third Quarter 2013 Operating Results CO-1686 and rucaparib demonstrated meaningful clinical activity in data presented at recent medical meetings 67 percent objective response rate demonstrated in heavily pretreated T790M+ NSCLC patients dosed at 900mg BID free base form of CO-1686 Dose escalation continues with improved hydrobromide
10/30/13
Summary ToggleClovis Oncology Announces First Patient Enrolled in ARIEL2 Study of Rucaparib in Ovarian Cancer Study to utilize DNA sequencing to determine the ovarian cancer patients most likely to benefit from rucaparib BOULDER, Colo. --(BUSINESS WIRE)--Oct. 30, 2013-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the global ARIEL2 (Assessment of Rucaparib in Ovarian Cancer Phase 2 Trial)
10/27/13
Summary ToggleClovis Oncology’s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results 67 percent objective response rate in heavily pretreated T790M+ patients dosed at 900mg BID of free base formulation New hydrobromide (HBr) formulation shows significantly improved exposures and reduced variability compared with free base in first cohort treated No rash or diarrhea of any grade, or
10/23/13
Summary ToggleClovis Oncology to Announce Third Quarter 2013 Financial Results and Host Webcast Conference Call on October 31 BOULDER, Colo. --(BUSINESS WIRE)--Oct. 23, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its third quarter 2013 financial results on Thursday, October 31, 2013 , after the market close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio
10/21/13
Summary ToggleClovis Oncology Announces Lung Cancer Diagnostic Collaboration with QIAGEN BOULDER, Colo. --(BUSINESS WIRE)--Oct. 21, 2013-- Clovis Oncology (NASDAQ: CLVS) announced today that the Company signed an agreement with QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) to develop a companion diagnostic test to identify the T790M resistance mutation in patients with epidermal
09/29/13
Summary ToggleOngoing Phase I Monotherapy Study of Rucaparib in Patients with Solid Tumors Demonstrates Clinical Activity, Establishes Dose and Schedule Objective responses seen in BRCA-mutant ovarian, breast and pancreatic cancer patients Disease control rate in BRCA-mutant ovarian cancer patients across all doses of 100% and 63% at 12 weeks and 24 weeks, respectively Rucaparib well-tolerated at recommended Phase II dose of 600 mg BID Consistent
09/04/13
Summary ToggleClovis Oncology to Present at the Morgan Stanley Global Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Sep. 4, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 , at 10:00 AM ET .
08/28/13
Summary ToggleClovis Oncology Announces First Patient Treated with Hydrobromide Salt Tablet Formulation of CO-1686 in its Ongoing Phase I/II Clinical Study BOULDER, Colo. --(BUSINESS WIRE)--Aug. 28, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today that it has dosed the first patient with its new hydrobromide salt tablet formulation of CO-1686 in its ongoing Phase I dose-finding portion of its Phase I/II clinical study.
08/01/13
Summary ToggleClovis Oncology Announces Second Quarter 2013 Operating Results ● Encouraging initial data for both CO-1686 and rucaparib presented at ASCO ● Dose established for rucaparib pivotal program ● Clinical transition to CO-1686 tablet formulation on track for August ● Additional Phase I data updates for CO-1686 and rucaparib expected at medical conferences later this
07/24/13
Summary ToggleClovis Oncology to Announce Second Quarter 2013 Financial Results and Host Webcast Conference Call on August 1 BOULDER, Colo. --(BUSINESS WIRE)--Jul. 24, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its second quarter 2013 financial results on Thursday, August 1, 2013 , before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on
06/13/13
Summary ToggleClovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jun. 13, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 486,110 shares.
06/13/13
Summary ToggleClovis Oncology Welcomes Two New Directors to its Board BOULDER, Colo. --(BUSINESS WIRE)--Jun. 13, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS), announced today the addition of two new members to its Board of Directors, Ginger Graham and Keith Flaherty , M.D. “We are delighted to add these two gifted individuals to our Board of Directors as the Company
06/11/13
Summary ToggleClovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jun. 11, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,333,334 shares of its common stock at $72.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $170
06/10/13
Summary ToggleClovis Oncology Announces Proposed Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Jun. 10, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $170 million . All shares of the common stock to be sold in the offering will be offered
06/03/13
Summary ToggleClovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR-mutant Non-Small Cell Lung Cancer Four RECIST partial responses observed in heavily pretreated T790M+ patients Three of four evaluable T790M+ patients treated at 900 mg BID achieved partial responses CO-1686 appears well-tolerated; no evidence of wild-type EGFR inhibition Activity correlates with higher drug exposure Phase II dose
06/03/13
Summary ToggleClovis Oncology’s Rucaparib Demonstrates Encouraging Results from Ongoing Phase I/II Monotherapy Study in Patients with Solid Tumors Objective responses seen in BRCA-mutant ovarian, breast and pancreatic cancer patients 89% clinical benefit rate in ovarian cancer patients across all doses Rucaparib well-tolerated at doses studied Consistent therapeutic drug exposures observed with BID dosing Phase II dose not yet defined; MTD
05/16/13
Summary ToggleClovis Oncology Announces Clinical Data to be Presented at ASCO Annual Meeting 2013 BOULDER, Colo. --(BUSINESS WIRE)--May. 16, 2013-- Clovis Oncology (NASDAQ:CLVS) announced that three abstracts ( ASCO Abstracts #2524, #2585, #2586) highlighting results from three Phase I studies of the company’s two lead compounds will be presented at the American Society of Clinical Oncology (
05/08/13
Summary ToggleClovis Oncology to Present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas BOULDER, Colo. --(BUSINESS WIRE)--May. 8, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast , the Company’s Chief Financial Officer and Executive Vice President, will present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 , at
05/07/13
Summary ToggleClovis Oncology Announces First Quarter 2013 Operating Results BOULDER, Colo. --(BUSINESS WIRE)--May. 7, 2013-- Clovis Oncology , Inc. (NASDAQ:CLVS) today reported financial results for its first quarter ended March 31, 2013 , and provided an update for its clinical development programs . This update describes, for the first time, the Company’s progress in
04/23/13
Summary ToggleClovis Oncology to Announce First Quarter 2013 Financial Results and Host Webcast Conference Call on May 7 BOULDER, Colo. --(BUSINESS WIRE)--Apr. 23, 2013-- Clovis Oncology, Inc. (Nasdaq:CLVS) will announce its first quarter 2013 financial results on Tuesday, May 7, 2013 , before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on
02/28/13
Summary ToggleClovis Oncology Announces 2012 Operating Results and 2013 Objectives BOULDER, Colo. --(BUSINESS WIRE)--Feb. 28, 2013-- Clovis Oncology , Inc. (NASDAQ:CLVS) today reported financial results for its quarter and year ended December 31, 2012 , and provided an update on the expected milestones for its clinical development programs for 2013.
02/25/13
Summary ToggleClovis Oncology to Present at the Cowen Health Care Conference in Boston BOULDER, Colo. --(BUSINESS WIRE)--Feb. 25, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President of Clovis, will present at the Cowen & Company 33 rd Annual Health Care Conference on Monday, March 4, 2013 , at 2:10 PM Eastern Time
02/14/13
Summary ToggleClovis Oncology to Announce Fourth Quarter/Year End 2012 Financial Results and Host Webcast Conference Call on February 28 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 14, 2013-- Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter/year end 2012 financial results on Thursday, February 28, 2013 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio
01/07/13
Summary ToggleClovis Oncology Announces 2013 Objectives and Financial Guidance BOULDER, Colo. --(BUSINESS WIRE)--Jan. 7, 2013-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced anticipated development milestones and financial guidance for 2013. Clovis currently has two clinical development programs and one drug discovery program underway.
01/02/13
Summary ToggleClovis Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Jan. 2, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President of Clovis will present at the 31 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2012 at 9:00 AM Pacific Time .
11/12/12
Summary ToggleClovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study No difference in overall survival versus gemcitabine in hENT1-low patients hENT1 biomarker also not predictive for gemcitabine outcomes BOULDER, Colo. --(BUSINESS WIRE)--Nov. 12, 2012-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the results from its LEAP (Low hENT1 and Adenocarcinoma of
11/08/12
Summary ToggleClovis Oncology to Present at the Credit Suisse Annual Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Nov. 8, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s president and CEO, will present at the Credit Suisse Annual Healthcare Conference on Thursday, November 15 , at 11:30am MST .
11/05/12
Summary ToggleClovis Oncology Announces Third Quarter 2012 Operating Results BOULDER, Colo. --(BUSINESS WIRE)--Nov. 5, 2012-- Clovis Oncology , Inc. (NASDAQ:CLVS) today reported financial results for the third quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.
10/18/12
Summary ToggleClovis Oncology to Announce Third Quarter 2012 Financial Results and Host Webcast Conference Call on November 5 BOULDER, Colo. --(BUSINESS WIRE)--Oct. 18, 2012-- Clovis Oncology, Inc. (Nasdaq:CLVS) will announce its third quarter 2012 financial results on Monday, November 5, 2012 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on
08/29/12
Summary ToggleClovis Oncology to Present at September Conferences in Boston and New York BOULDER, Colo. --(BUSINESS WIRE)--Aug. 29, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Company management will participate in the following two investor conferences during the month of September: On September 6 , Erle T. Mast , the Company’s CFO, will present at the Stifel
08/08/12
Summary ToggleClovis Oncology Announces Second Quarter 2012 Operating Results BOULDER, Colo. --(BUSINESS WIRE)--Aug. 8, 2012-- Clovis Oncology , Inc. (NASDAQ:CLVS) today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.
08/06/12
Summary ToggleFoundation Medicine and Clovis Oncology Announce Diagnostic Collaboration Foundation Medicine to provide technology and analysis to inform companion diagnostic development for Clovis’ PARP inhibitor product candidate rucaparib CAMBRIDGE, Mass. & BOULDER, Colo. --(BUSINESS WIRE)--Aug. 6, 2012-- Foundation Medicine, Inc. and Clovis Oncology, Inc.
07/30/12
Summary ToggleClovis Oncology to Announce Second Quarter 2012 Financial Results and Host Webcast Conference Call on August 8 BOULDER, Colo. --(BUSINESS WIRE)--Jul. 30, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its second quarter 2012 financial results on Wednesday, August 8, 2012 , before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast
07/16/12
Summary ToggleClovis Oncology and Array BioPharma Announce Agreement to Discover Novel Mutant KIT Inhibitor Collaboration to discover an innovative treatment approach for gastrointestinal stromal tumors (GIST) patients with disease resistant to current therapies KIT mutations drive GIST in approximately 80 percent of patients Array to discover novel KIT inhibitor; broad experience in designing selective
05/08/12
Summary ToggleClovis Oncology to Present at the Bank of America Merrill Lynch 2012 Health Care Conference BOULDER, Colo. --(BUSINESS WIRE)--May. 8, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Company management will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 8:00 AM Pacific Time .
05/08/12
Summary ToggleClovis Oncology Announces First Quarter 2012 Operating Results Completed enrollment in pivotal LEAP study for CO-101 in pancreatic cancer Confirmed final hENT1-low percentage in LEAP study is 64 percent Initiated clinical development for CO-1686 in NSCLC In April, raised $70.5 million from a public offering of common stock BOULDER, Colo.
04/24/12
Summary ToggleClovis Oncology to Announce First Quarter 2012 Financial Results and Host Webcast Conference Call on May 8 BOULDER, Colo., Apr 24, 2012 (BUSINESS WIRE) --Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its first quarter 2012 financial results on Tuesday, May 8, 2012, before the open of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast on Tuesday,
04/03/12
Summary ToggleClovis Oncology Announces Pricing of Public Offering BOULDER, Colo. --(BUSINESS WIRE)--Apr. 3, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of its underwritten public offering of 3,750,000 shares of its common stock at $20.00 per share, before underwriting discounts and commissions.
03/28/12
Summary ToggleClovis Oncology Announces Enrollment of First Patient in First Human Study of Oral EGFR Mutant-Selective Inhibitor CO-1686 First of two planned Phase I/II studies of novel covalent EGFR inhibitor BOULDER, Colo. --(BUSINESS WIRE)--Mar. 28, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site.
03/26/12
Summary ToggleClovis Oncology Completes Enrollment in Pivotal LEAP Trial of CO-101 versus Gemcitabine in Metastatic Pancreatic Cancer First study to prospectively explore association of tumor hENT-1 expression with overall survival; first study of a targeted therapy with a companion diagnostic in pancreatic cancer BOULDER, Colo. --(BUSINESS WIRE)--Mar. 26, 2012-- Clovis Oncology, Inc.
03/23/12
Summary ToggleClovis Oncology Announces Proposed Public Offering of Common Stock BOULDER, Colo. --(BUSINESS WIRE)--Mar. 23, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ( SEC ) relating to a proposed underwritten public offering of $75 million of shares of its
03/07/12
Summary ToggleClovis Oncology Announces 2011 Operating Results 2011 accomplishments position company for a meaningful 2012 BOULDER, Colo. --(BUSINESS WIRE)--Mar. 7, 2012-- Clovis Oncology , Inc. (NASDAQ:CLVS) today reported financial results for its quarter and year ended December 31, 2011 , and provided an update on the progress of its clinical development
02/23/12
Summary ToggleClovis Oncology to Announce Fourth Quarter and Year-End 2011 Financial Results, Host Webcast Conference Call on March 8 Also presenting at Cowen Health Care Conference in Boston on March 6 BOULDER, Colo. --(BUSINESS WIRE)--Feb. 23, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its fourth quarter and year-end 2011 financial results on Thursday, March 8, 2012 , before the open of the U.S.
02/10/12
Summary ToggleCompany Profile for Clovis Oncology Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and
02/06/12
Summary ToggleClovis Oncology to Present at the Leerink Swann Global Healthcare Conference and Citi 2012 Global Health Care Conference in February BOULDER, Colo. --(BUSINESS WIRE)--Feb. 6, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Company management will present at the Leerink Swann Global Healthcare Conference on Wednesday, February 15, 2012 at 1:30 PM Eastern Time and the Citi 2012 Global Health Care Conference on
01/19/12
Summary ToggleClovis Oncology Announces FDA Acceptance of Investigational New Drug Application for Oral EGFR Mutant-Selective Inhibitor CO-1686 Clinical studies to begin Q2 2012 Initial development focused on T790M mutation in NSCLC T790M is the dominant cause of acquired resistance to Tarceva ® /Iressa ® in mutant EGFR NSCLC Unmet medical need with no approved targeted therapy BOULDER, Colo. --(BUSINESS WIRE)--Jan.
01/09/12
Summary ToggleClovis Oncology Announces Size of Initial hENT1-Low Population in Pivotal LEAP Trial and Provides Financial Guidance for 2012 65 percent of the initial 250 patients enrolled in the study are hENT1-low Percentage consistent with retrospective analyses Clovis performed from other pancreatic cancer studies Company expects $67 - $72 million cash burn for 2012 BOULDER, Colo. --(BUSINESS WIRE)--Jan.
01/03/12
Summary ToggleClovis Oncology to Present at the 30th Annual J.P. Morgan Healthcare Conference BOULDER, Colo. --(BUSINESS WIRE)--Jan. 3, 2012-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President of Clovis will present at the 30 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2012 at 2:30 PM Pacific Time .
11/29/11
Summary ToggleClovis Oncology Announces Exercise of Underwriters' Option to Purchase 700,000 Shares of Clovis Oncology Common Stock BOULDER, Colo., Nov 29, 2011 (BUSINESS WIRE) -- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the underwriters of its recently completed initial public offering have exercised their option to purchase an additional 700,000 shares of Clovis Oncology common stock to cover over-allotments.
11/15/11
Summary ToggleClovis Oncology Announces Pricing of Initial Public Offering BOULDER, Colo., Nov 15, 2011 (BUSINESS WIRE) -- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of its initial public offering of 10,000,000 shares of its common stock at $13.00 per share, before underwriting discounts and commissions.
06/02/11
Summary ToggleClovis Oncology, Inc. Receives License for Worldwide Development and Commercialization Rights to Pfizer’s Oral and IV PARP Inhibitor PF-01367338       •   PF-01367338 is currently in Phase 1/2 development in combination with chemotherapy in patients with solid tumors   •   Phase 2 data from IV formulation demonstrate encouraging activity and safety profile   •   Clovis to assume
06/02/11
Summary ToggleRoche and Clovis Oncology to Co-develop EGFR Companion Diagnostic       •   Collaboration focused on personalized treatment of Non-small-cell Lung Cancer BOULDER, CO, and PLEASANTON, CA, June 2, 2011 – Clovis Oncology, Inc. and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that they have entered into an agreement to
11/11/10
Summary ToggleClavis Pharma and Clovis Oncology Extend Partnership and Sign New $205 Million Deal for the Development and Commercialisation of Anti-Cancer Agent CP-4126 in Asia and Rest of the World       •   New deal expands existing relationship to include global rights to CP-4126           •   Clavis Pharma to receive up to $205 million in additional staged payments, including a $10 million signing fee, and tiered double-digit
05/25/10
Summary ToggleClovis Oncology and Avila Therapeutics Sign $209 Million Partnership for the Worldwide Development and Commercialization of EGFR Mutant-Selective Inhibitor       •   Avila's oral, small molecule program targets cancer-causing mutant forms of the EGF receptor (EGFR)   •   Innovative treatment approach for non-small cell lung cancer (NSCLC) patients with disease resistant to current therapy   •
04/22/10
Summary ToggleClovis Oncology, Inc. Signs an Agreement with Ventana Medical Systems to Develop Companion Diagnostic Test for CO-101       •   IHC assay to identify hENT1-low pancreatic cancer patients         •   May help lead to improved outcomes for 50% of pancreatic cancer patients BOULDER, Colo., April 22, 2010 – Clovis Oncology, Inc. and Ventana Medical Systems, Inc.
01/25/10
Summary ToggleClovis Oncology Receives Orphan Drug Designation for CO-101 BOULDER, CO – January 25, 2010. Clovis Oncology Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that the FDA has granted orphan-drug designation for eladic
11/24/09
Summary ToggleClavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126       •   CP-4126 is a novel, lipid-conjugated form of gemcitabine designed by Clavis Pharma to improve treatment outcomes in patients with pancreatic and other solid tumours   •   Clavis Pharma to receive up to $380 million in staged payments,
05/21/09
Summary ToggleClovis Oncology Raises $146 Million in Start-Up Financing       •   New company founded by members of former Pharmion executive team   •   Company focused on acquiring, developing and marketing innovative anti-cancer compounds      BOULDER, Colo., May 21, 2009 – Clovis Oncology,
Investor Relations and Corporate Communications Contacts
Breanna Burkart
Phone: 303.625.5023
E-mail: bburkart@clovisoncology.com
Anna Sussman
Phone: 303.625.5022
E-mail: asussman@clovisoncology.com